Toll-like Receptors 2, 3, and 4 in Childhood Acute Lymphocytic Leukemia

• Autor(a) principal: Cruz, Matheus Loureiro da Silva
• Data de Publicação: 2023
• Outros Autores: Santos, Rafael Pereira dos, Souza, Barbara Kunzler, Jaeger, Mariane da Cunha, Silva, Camila Alves da, Gregianin, Lauro José, Loss, Jiseh Fagundes, Marques, Rebeca Ferreira, Brunetto, Algemir Lunardi, Brunetto, André Tesainer, Roesler, Rafael, Farias, Caroline Brunetto de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista Brasileira de Cancerologia (Online)
• Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/3676
• topic: leucemia-linfoma linfoblástico de células precursoras; receptores Toll-like; precursor cell lymphoblastic leukemia-lymphoma; Toll-like receptors; leucemia-linfoma linfoblástico de células precursoras; receptores Toll-like

Introduction: Acute lymphocytic leukemia (ALL) is the most common cancer type in children and accounts for 80% of pediatric leukemias. Novel targets are necessary to improve survival rates for refractory and relapsed disease. There is accumulating evidence that Toll-like Receptor (TLR) signaling may be associated with outcomes in cancer however little has been described in leukemias. Objective: Analyze the expression and contribution of TLRs to the development of childhood ALL. Method: To evaluate the effect of specific TLR2, TLR3, and TLR4 agonists on the viability and proliferation of childhood ALL cell lines and to analyzed the mRNA expression of these types of TLR in bone marrow blast cells at diagnosis (D0) and induction (D35) in pediatric ALL patients. Results: Treatment with TLR agonists reduced the cell viability of Jurkat and Sup-B15 cell lines. Cell cycle distribution in Jurkat was altered, reducing polyploid cells and increasing sub-G1 phase. Conclusion: It was observed that the cell viability of the cell lines responded with different sensitivities to the agonists. The polyploidy associated with tumor malignancy was reduced, in addition to the increase in the sub-G1 phase indicating an increase in apoptosis. There were differences in TLR expression at D35 between groups at risk of the disease. Patients with high expression of TLR2 and low expression of TLR4 on D35 demonstrated a worse prognosis.